Диссертация (1139774), страница 25
Текст из файла (страница 25)
- P. 360-9.152. KasperS.,ResingerE.AnticholinergicCognitiveBurdenScale//Psychoneuroendocrinology. - 2003. - V. 28 (1) - Р. 27-38.153. Kaushal R., Bates D.W., Landrigan C., McKenna K.J., Clapp M.D., Federico F.,Goldmann D.A. Medication errors and adverse drug events in pediatric inpatients //Journal of the American Medical Association. - 2001. - V. 285(16). - P. 2114-20.154.
Kennerly D.A., Kudyakov R., da Graca B., Saldaña M., Compton J., NicewanderD., Gilder R. Characterization of Adverse Events Detected in a Large Health CareDelivery System Using an Enhanced Global Trigger Tool over a Five-Year Interval //Health Services Research. - 2014. - V. 49(5). - P.1407-25.155. Kilian R., Dietrich S., Toumi M., Angermeyer M.C. Quality of life in personswith schizophrenia in out-patient treatment with first- or second-generationantipsychotics // Acta Psychiatrica Scandinavica. - 2004.
- V. 110. - P. 108-18.156. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychoticdrugs: a critical analysis // Psychopharmacology (Berl). - 1996. - V. 124. - P. 2-34.157. Kobylecki C.J., Jakobsen K.D., Hansen T., Jakobsen I.V., Rasmussen H.B.,Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophreniainpatients: a retrospective matched case-control study // Neuropsychobiology. - 2009. V. 59(4).
- P. 222-6.150158. Koro C.E., Fedder D.O., L’Italien G.J., Weiss S.S., Magder L.S., Kreyenbuhl J.,Revicki D.A., Buchanan R.W. Assessment of independent effect of olanzapine andrisperidone on risk of diabetes among patients with schizophrenia: population basednested case-control study // British Medical Journal. - 2002. - V. 325. - P. 243-7.159.
Landrigan C.P., Parry G.J., Bones C.B., Hackbarth A.D., Goldmann D.A., SharekP.J. Temporal trends in rates of patient harm resulting from medical care // NewEngland Journal of Medicine. - 2010. - V. 363(22). - P. 2124-34.160. Lang K., Meyers J.L., Korn J.R., Lee S., Sikirica M., Crivera C., Dirani R.,Menzin J. Medication adherence and hospitalization among patients with schizophreniatreated with antipsychotics.
// Psychiatric Services - 2010. - V. 61(12). - P. 1239-47.161. Lehman A.F., Lieberman J.A., Dixon J.A., McGlashan T.H., Miller A.L., PerkinsD.O., Kreyenbuhl J. Practice Guideline for the Treatment of Schizophrenia, 2nd edition.American Psychiatric Association, Steering Committee on Practice Guidelines.Washington, DC, USA. 2004.162. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocialtreatment of nonadherence in schizophrenia // J Clin Psychiatry. - 2006. - V. 67(5). - P.3-8.163.
Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., Davis J.M.Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: asystematic review and meta-analysis // Lancet. - 2012. - V. 379 (9831). - P. 2063-71.164. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychoticsversus low-potency conventional antipsychotics: a systematic review and meta-analysis// Lancet. - 2003. - V. 361.
- P. 1581-9.165. Lieberman J.A. Managing Anticholinergic Side Effects // Primary CareCompanion Journal of Clinical Psychiatry. - 2004. - V. 6(2). - P. 20–3.166. Lieberman J.A. Understanding the mechanism of action of atypical antipsychoticdrugs. A review of compounds in use and development // British Journal of Psychiatry.- 1993.
- V. 163(22). - P. 7-18.167. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoyJ., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and151safety of atypical and conventional antipsychotic drugs in first-episode psychosis: arandomized, double-blind trial of olanzapine versus haloperidol // American Journal ofPsychiatry. - 2003. - V. 160 (8). - P. 1396–1404.168. Llerena A., Dahl M.L., Ekqvist B., Bertilsson L.
Haloperidol disposition isdependent on the debrisoquine hydroxylation phenotype: increased plasma levels of thereduced metabolite in poor metabolizers // Therapeutic Drug Monitoring. - 1992. - V.14(3). - P. 261-4.169. Llorca P., Chereau I., Bayle F., Lancon C. Tardive dyskinesias andantipsychotics: a review // European Psychiatry. - 2002.
- V. 17(3). - P. 129-38.170. Lloyd H.M., Markwick A.J., Page E.R., Lewis S., Barnes T.R.E. Attitudes toatypical and conventional antipsychotic drug treatment in clinicians participating in theCUtLASS study // International Journal of Psychiatry in Clinical Practice. - 2005.
- V.9. - P. 35-40.171. Lou Y.C., Ying L., Bertilsson L., Sjöqvist F. Low frequency of slow debrisoquinehydroxylation in a native Chinese population // Lancet. - 1987. - V. 2. - P. 852-3.172. Mackowiak M., Czyrak A., Wedzony K. The involvement of 5-HT1a serotoninreceptors in the pathophysiology and pharmacotherapy of schizophrenia // PsychiatriaPolska. - 2000. - V. 34 (4). - P. 607-21.173. MacNeil R.R., Müller D.J. Genetics of Common Antipsychotic-Induced AdverseEffects // Molecular Neuropsychiatry. - 2016.
- V. 2. - P. 61-78.174. Malhotra A.K., Correll C.U., Chowdhury N.I., Müller D.J., Gregersen P.K., LeeA.T., Tiwari A.K., Kane J.M., Fleischhacker W.W., Kahn R.S., Ophoff R.A., MeltzerH.Y., Lencz T., Kennedy J.L. Association between common variants near themelanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain //Archives of General Psychiatry. - 2012. - V. 69(9). - P.
904-12.175. Mannheimer B., Holm J., Koukel L., Bertilsson L., Osby U., Eliasson E.Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype inschizophrenic patients // European Journal of Clinical Pharmacology. - 2014. - V. 70(6).- P. 695-9.152176. Mapes R. Aspects of British general practitioners prescribing // Medical Care. 1977. - V. 760. - P.
371-81.177. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R., AnnableL. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidenceand management strategies in patients with schizophrenia // Canadian Journal ofPsychiatry. - 2005. - V. 50(11), P. 703-14.178. Mason M.N., Johnson C.E., Piasecki M. Ziprasidone-induced acute dystonia //American Journal of Psychiatry. - 2005. - V.
162 (3). - P. 625-6.179. McDonnell P.J., Jacobs M.R. Hospital admissions resulting from preventableadverse drug reactions // Annals of Pharmacotherapy. - 2002. - V. 36(9). - Р. 1331-6.180. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role indrugs to treat schizophrenia // Progress in Neuro-Psychopharmacology & BiologicalPsychiatry. - 2003.
- V. 27. - P. 1159-72.181. Mihara K., Kondo T., Suzuki A., Yasui-Furukori N., Ono S., Sano A., KoshiroK., Otani K., Kaneko S. Relationship between functional dopamine D2 and D3receptors gene polymorphisms and neuroleptic malignant syndrome // American Journalof Medical Genetics Part B: Neuropsychiatric Genetics. - 2003. - V.117B(1). - P. 57-60.182. Miller D.D., Caroff S.N., Davis S.M., Rosenheck R.A., McEvoy J.P., Saltz B.L.,Riggio S., Chakos M.H., Swartz M.S., Keefe R.S.E., Stroup T.S., Lieberman J.A.Extrapyramidal side-effects of antipsychotics in a randomised trial, the ClinicalAntipsychotic Trials of Intervention Effectiveness (CATIE) Investigators // BritishJournal of Psychiatry.
- 2008. - V. 193(4). - P. 279-88.183. Modestin J. Krapf R., Böker W. A fatality during haloperidol treatment:mechanism of sudden death // American Journal of Psychiatry. - 1981. - V. 138(12). - P.1616-17.184. Montastruc J.L., Laborie I., Bagheri H., Senard J.M., Drug-induced orthostatichypotension. A five-year experience in a regional pharmacovigilance centre in France //Clinical Drug Investigation. - 1997. - V. 14(1). - P. 61-5.153185. Morrison P., Meehan T., Stomski N.J.
Living with antipsychotic medication sideeffects: the experience of Australian mental health consumers // International Journal ofMental Health Nursing. - 2015. - V. 24(3). -P. 253-61.186. Mortensen P.B., Juel K. Mortality and causes of death in schizophrenic patients inDenmark // Acta Psychiatrica Scandinavica. - 1990. - V. 81. - P. 372-7.187. MrazekD.A.,LermanC.Facilitatingclinicalimplementationofpharmacogenomics // Journal of the American Medical Association. - 2011. - V.
306. P. 304-5.188. Müller D.J., Kekin I., Kao A.C., Brandl E.J. Towards the implementation ofCYP2D6 and CYP2C19 genotypes in clinical practice: update and report from apharmacogenetic service clinic // International Review of Psychiatry. - 2013. - V. 25. P. 554-71.189. Mullins C.D., Obeidat N.A., Cuffel B.J., Naradzay J., Loebel A.D. Risk ofdiscontinuation of atypical antipsychotic agents in the treatment of schizophrenia //Schizophrenia Research. - 2008. - V. 98(1-3). - P. 8-15.190. Nappo S.A., de Oliveira L.G., Sanchez Zv., Carlini Ede A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
